Michael Berry
Chief Tech/Sci/R&D Officer at EVEREST MEDICINES LIMITED
Profile
Michael Berry is currently the Chief Technology Officer at Everest Medicines Ltd.
He previously worked as the Senior Director of Bioprocess Development at Portola Pharmaceuticals, Director at ARCA biopharma, Director of Manufacturing Sciences & Technology at Novartis Vaccines & Diagnostics SL, and Vice President at Dynavax Technologies Corp.
He is also the Chief Technical Operations Officer at Clover Biopharmaceuticals Ltd.
Berry received his undergraduate degree from De Montfort University, his graduate degree from The University of Manchester, and his doctorate from the University of Manitoba.
Michael Berry active positions
| Companies | Position | Start |
|---|---|---|
| EVEREST MEDICINES LIMITED | Chief Tech/Sci/R&D Officer | 2023-06-14 |
Former positions of Michael Berry
| Companies | Position | End |
|---|---|---|
| DYNAVAX TECHNOLOGIES CORPORATION | Corporate Officer/Principal | 2017-07-31 |
| PORTOLA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2015-01-31 |
| Novartis Vaccines & Diagnostics SL | Corporate Officer/Principal | 2013-08-31 |
| ARCA BIOPHARMA, INC. | Director/Board Member | 2009-04-30 |
| CLOVER BIOPHARMACEUTICALS, LTD. | Chief Tech/Sci/R&D Officer | - |
Training of Michael Berry
| The University of Manchester | Graduate Degree |
| University of Manitoba | Doctorate Degree |
| De Montfort University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| DYNAVAX TECHNOLOGIES CORPORATION | Health Technology |
| ARCA BIOPHARMA, INC. | Health Technology |
| EVEREST MEDICINES LIMITED | Health Technology |
| CLOVER BIOPHARMACEUTICALS, LTD. | Health Technology |
| Private companies | 2 |
|---|---|
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
| Novartis Vaccines & Diagnostics SL |
- Stock Market
- Insiders
- Michael Berry
